SCHEMBL8655175

SCHEMBL8655175

O=C(Cl)Oc1cccc2c1Cc1ccccc1-2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
HTR2B P41595 3/20 0.44
HTR7 P34969 2/20 0.44
PNMT P11086 1/20 0.42
KDM4E B2RXH2 3/20 0.39
MAPK1 P28482 1/20 0.39
HSP90AA1 P07900 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SRD5A2 P31213 1/20 0.38
HTR2C P28335 2/20 0.36
DRD2 P14416 2/20 0.36
ADRA1D P25100 1/20 0.36
HTR2A P28223 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8840922 0.87 RAB9A (0.54) RAB9ANPC1HTR2BHTR7PNMT
SCHEMBL20917777 0.85 RAB9A (0.49) RAB9ANPC1HTR2BHTR7PNMT
SCHEMBL30616301 0.85 RAB9A (0.49) RAB9ANPC1HTR2BHTR7PNMT
SCHEMBL30643818 0.84 HTR2B (0.51) RAB9ANPC1HTR2BHTR7PNMT
SCHEMBL4675573 0.84 HTR2B (0.51) RAB9ANPC1HTR2BHTR7PNMT
SCHEMBL2131214 0.84 RAB9A (0.55) RAB9ANPC1HTR2BHTR7PNMT
SCHEMBL30695173 0.83 RAB9A (0.47) RAB9ANPC1HTR2BHTR7PNMT
SCHEMBL20886929 0.81 TOP1 (0.51) RAB9ANPC1HTR2BHTR7PNMT
SCHEMBL29112976 0.81 RAB9A (0.46) RAB9ANPC1HTR2BHTR7PNMT
SCHEMBL2552485 0.80 RAB9A (0.51) RAB9ANPC1HTR2BHTR7PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113292456-B Preparation method of N-fluorenylmethoxycarbonyl-L-aspartic acid-4-tert-butyl ester 常州吉恩药业有限公司 2022-04-29 CN claimed
CN-113292456-A Preparation method of N-fluorenylmethoxycarbonyl-L-aspartic acid-4-tert-butyl ester 常州吉恩药业有限公司 2021-08-24 CN claimed
WO-2014031204-A2 CARBOHYDRATE-SELECTIVE RECEPTORS NEW YORK UNIVERSITY (US) 2014-02-27 WO claimed
CN-116375706-B Abamectin sodium key intermediate and preparation method thereof 时森海(杭州)医药科技有限公司 2025-02-14 CN disclosed
CN-116375706-A Abamectin sodium key intermediate and preparation method thereof 时森海(杭州)医药科技有限公司 2023-07-04 CN disclosed
CN-113292456-B Preparation method of N-fluorenylmethoxycarbonyl-L-aspartic acid-4-tert-butyl ester 常州吉恩药业有限公司 2022-04-29 CN disclosed
CN-113292456-A Preparation method of N-fluorenylmethoxycarbonyl-L-aspartic acid-4-tert-butyl ester 常州吉恩药业有限公司 2021-08-24 CN disclosed
US-9428497-B2 Precursor compounds for the radiosynthesis of [18F] norchloro-fluorohomoepibatidine ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) 2016-08-30 US disclosed
US-9296688-B2 Carbohydrate-selective receptors NEW YORK UNIVERSITY (US) 2016-03-29 US disclosed
US-20150259338-A1 PRECURSOR COMPOUNDS FOR THE RADIOSYNTHESIS OF [18F] NORCHLORO-FLUOROHOMOEPIBATIDINE ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (GE) 2015-09-17 US disclosed
US-20150141480-A1 CARBOHYDRATE-SELECTIVE RECEPTORS NEW YORK UNIVERSITY (US) 2015-05-21 US disclosed
EP-2739622-A1 PRECURSOR COMPOUNDS FOR THE RADIOSYNTHESIS OF [18F]NORCHLORO-FLUOROHOMOEPIBATIDINE ABX Advanced Biochemical Compounds GmbH (DE) 2014-06-11 EP disclosed
WO-2014031204-A2 CARBOHYDRATE-SELECTIVE RECEPTORS NEW YORK UNIVERSITY (US) 2014-02-27 WO disclosed
WO-2013017585-A1 PRECURSOR COMPOUNDS FOR THE RADIOSYNTHESIS OF [18F] NORCHLORO-FLUOROHOMOEPIBATIDINE ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) 2013-02-07 WO disclosed
US-5780307-A IMMUNOPHILIN THAT SPECIFICALLY BINDS FK-506, RAPAMYCIN AND-OR CYCLOSPORIN SOLDIN STEVEN J (US) 1998-07-14 US disclosed
US-5698448-A Immunosuppressive drug binding proteins and use CHILDREN'S RESEARCH INSTITUTE 1997-12-16 US disclosed
EP-0641354-A4 OLIGONUCLEOTIDES HAVING AMINOHYDROCARBON PHOSPHONATE MOIETIES. PHARMAGENICS INC (US) 1996-01-10 EP disclosed
WO-1995031572-A1 AMINOHYDROCARBON PHOSPHONATE OLIGONUCLEOTIDES AND USES THEREFOR PHARMGENICS, INC. (US) 1995-11-23 WO disclosed
EP-0641354-A1 OLIGONUCLEOTIDES HAVING AMINOHYDROCARBON PHOSPHONATE MOIETIES PHARMAGENICS, INC. (US) 1995-03-08 EP disclosed
WO-1993011148-A1 OLIGONUCLEOTIDES HAVING AMINOHYDROCARBON PHOSPHONATE MOIETIES PHARMAGENICS, INC. (US) 1993-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259338-A1 PRECURSOR COMPOUNDS FOR THE RADIOSYNTHESIS OF [18F] NORCHLORO-FLUOROHOMOEPIBATIDINE CBR3, CBR1, IDH1 RAB9A 1105/4885NPC1 523/4885HTR2B 1492/4885
US-20150141480-A1 CARBOHYDRATE-SELECTIVE RECEPTORS GPR119, GCGR, GALR1 RAB9A 1799/4885NPC1 489/4885HTR2B 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.